halofuginone has been researched along with Anoxemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babicheva, A; Balistrieri, F; Carr, SG; Chen, J; Izadi, A; Jain, PP; Lai, N; Makino, A; Rahimi, S; Rodriguez, M; Shyy, JY; Simonson, T; Song, S; Thistlethwaite, PA; Valdez-Jasso, D; Wang, J; Xiong, M; Yuan, JX; Zhao, T; Zheng, Q | 1 |
| Bian, ZX; Du, J; Lin, SH; Liu, J; Mu, HX; Wang, D; Wang, HS; Xiao, HT; Yang, D; Zhao, L | 1 |
2 other study(ies) available for halofuginone and Anoxemia
| Article | Year |
|---|---|
Halofuginone, a promising drug for treatment of pulmonary hypertension.
Topics: Animals; Calcium; Hypertension, Pulmonary; Hypoxia; Mice; Myocytes, Smooth Muscle; Pharmaceutical Preparations; Phosphatidylinositol 3-Kinases; Piperidines; Pulmonary Artery; Quinazolinones | 2021 |
Halofuginone reduces the inflammatory responses of DSS-induced colitis through metabolic reprogramming.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Body Weight; Colitis; Cytokines; Dextran Sulfate; Disease Models, Animal; Energy Metabolism; Enzyme Activation; Fatty Acids; Gene Expression; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammation Mediators; Liver; Male; Metabolic Networks and Pathways; Mice; Models, Biological; Oxidation-Reduction; Peroxidase; Phenotype; Piperidines; Quinazolinones; RNA, Messenger; Spleen | 2016 |